April 20, 2020

Study suggests that the dual mechanism of a new antiepileptic drug may explain its effectiveness in Dravet Syndrome

In addition to promoting the release of serotonin, a brain chemical typically associated with feelings of well-being and happiness, fenfluramine also seems to control the activity of sigma-1 receptors found on the surface of nerve cells, a study has found.

This dual mechanism of action is likely responsible for the deep and sustained effectiveness of the medication at reducing the frequency of seizures in children and young adults with Dravet syndrome, researchers noted.

Results of the study, “Fenfluramine acts as a positive modulator of sigma-1 receptors,” were published in the journal Epilepsy & Behavior.

Related News

February 14, 2024

Fintepla Safely Reduces Seizures in Children Younger than 2, Study Finds

Treatment with Fintepla (fenfluramine) appeared to be reasonably safe and lower seizure frequency in five children with Dravet syndrome who started on the therapy before they were two years old.

January 12, 2024

Seizures Identified as Potential Cause of Sudden Unexplained Deaths in Children

“These findings show that seizures are much more common than patients’ medical histories suggest, and that further research is needed to determine if seizures are frequent occurrences in sleep-related deaths in toddlers, and potentially in infants, older children, and adults,”

December 14, 2023

The Mozart Effect Myth: Listening to Music Does Not Help Against Epilepsy

“Mozart’s music is beautiful, but unfortunately, we cannot expect relief from epilepsy symptoms from it”, conclude the researchers.